Robert L Kortum

16PUBLICATIONS

95CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (16)

Sort by Publication Date:

|Oct 29, 2026

ATR inhibitors and gemcitabine synergize to induce cell death in TP53-mutant, ATRX-wildtype uterine leiomyosarcoma.

|Sep 08, 2026

HRAS promotes mutant NRAS-driven transformation with codon and allele specificity.

|Dec 04, 2025

Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer.

Hannah E Price, Stacey Stauffer, Hyun Lee

|Nov 25, 2025

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.

Brianna R Daley, Patricia L Theard, Jacob M Hughes

|Sep 16, 2025

Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers.

Nancy E Sealover, Bridget A Finniff, Jacob M Hughes

|Oct 22, 2024

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.

Brianna R Daley, Nancy E Sealover, Bridget A Finniff

Pageof 3

Frequent Collaborators

Nancy E Sealover

Marielle E Yohe

Matthew D Wilkerson

Jacob M Hughes

Joseph P LaMorte

Kaja Kostyrko

Elijah F Edmondson

Erin Sheffels

Clifton L Dalgard

Bridget A Finniff

Frequent Collaborators

Nancy E Sealover

Marielle E Yohe

Matthew D Wilkerson

Jacob M Hughes